Islet Dysfunction Induced by Niemann-Pick C1 (NPC1) Heterozygous Mutation Combined with High-fat Diet in C57BL/6C Mice

Author(s): Linhai Zou, Ji Zhou, Guohui Jiang, Lixia Ji

Male patients with NPC1 heterozygous mutation (Npc1+/-) are prone to obesity and diabetes, yet the mechanism remains unclear. In this study, male Npc1+/- mice (C57BL/6C-Npc1) were used to evaluate the effects of NPC1 heterozygous mutation combined with 60% high-fat diet (HFD) on glucolipid metabolism, cholesterol accumulation, islet dysfunction and β-cell dedifferentiation. Compared with male HFD-Npc1+/+ or Npc1+/- mice fed with low-fat diet (LFD), body weight of male HFD-Npc1+/- mice gradually increased with elevated levels of fasting blood glucose (FBG), total cholesterol (TC) and triglyceride (TG), showing hyperinsulinemia and typical characteristics of diabetes. Oral glucose tolerance test (OGTT) and insulin tolerance test (ITT) indicated that HFD-Npc1+/- mice developed marked oral glucose intolerance and severe systemic insulin resistance after 4 months. TC and TG were accumulated in both liver and pancreas. The HE results confirmed the large diameter of epididymal adipocytes in HFD-Npc1+/- mice. Furthermore, protein levels of insulin, 4E-BP1, p-S6 and PDX1 were suppressed obviously in β cells of HFD-Npc1+/- mice, while expression of glucagon and precursor marker ALDH1A3 increased, indicating the typical dedifferentiation occurred in β cells. This study partly reveals the underlying mechanism of susceptibility of obesity and diabetes in Npc1+/- male mice induced by 60% HFD. High metabolic stress and abnormal cholesterol metabolism in islets more directly lead to the dedifferentiation and dysfunction of β cells, to aggravate the process from obesity to diabetes.

NPC1, Diabetes, Hyperglycemia, β-cells, Dedifferentiation

1. 1. Brown MS, Goldstein JL (1986) A receptor-mediated pathway for cholesterol homeostasis. Science 25: 583-602.
2. 2. Lamri A, Pigeyre M, Garver WS, Meyre D (2018) The Extending Spectrum of NPC1-Related Human Disorders: From Niemann-Pick C1 Disease to Obesity. Endocr Rev 39: 192-220.
3. 3. Garver WS, Francis GA, Jelinek D, Shepherd G, Flynn J, et al. (2007) The National Niemann-Pick C1 disease database: report of clinical features and health problems. Am J Med Genet A 143a: 1204-1211.
4. 4. Chen FW, Gordon RE, Ioannou YA (2005) NPC1 late endosomes contain elevated levels of non-esterified ('free') fatty acids and an abnormally glycosylated form of the NPC2 protein. Biochem J 390: 549-561.
5. 5. Higgins ME, Davies JP, Chen FW, Ioannou YA (1999) Niemann-Pick C1 is a late endosome-resident protein that transiently associates with lysosomes and the trans-Golgi network. Mol Genet Metab 68: 1-13.
6. 6. Naureckiene S, Sleat DE, Lackland H, Fensom A, Vanier MT, et al. (2000) Identification of HE1 as the second gene of Niemann-Pick C disease. Science 290: 2298-2301.
7. 7. Cologna SM, Rosenhouse-Dantsker A (2019) Insights into the Molecular Mechanisms of Cholesterol Binding to the NPC1 and NPC2 Proteins. Adv Exp Med Biol 1135: 139-160.
8. 8. Erickson RP (2018) Do GWAS and studies of heterozygotes for NPC1 and/or NPC2 explain why NPC disease cases are so rare? J Appl Genet 59: 441-447.
9. 9. Loftus SK, Morris JA, Carstea ED, Gu JZ, Cummings C, et al. (1997) Murine model of Niemann-Pick C disease: mutation in a cholesterol homeostasis gene. Science 277: 232-235.
10. 10. Meyre D, Delplanque J, Chèvre JC, Lecoeur C, Lobbens S, et al. (2009) Genome-wide association study for early-onset and morbid adult obesity identifies three new risk loci in European populations. Nat Genet 41: 157-159.
11. 11. Pfeffer SR (2019) NPC intracellular cholesterol transporter 1 (NPC1)-mediated cholesterol export from lysosomes. J Biol Chem 294: 1706-1709.
12. 12. Yu XH, Jiang N, Yao PB, Zheng XL, Cayabyab FS, et al. (2014) NPC1, intracellular cholesterol trafficking and atherosclerosis. Clin Chim Acta 429: 69-75.
13. 13. Pentchev PG, Comly ME, Kruth HS, Patel S, Proestel M, et al. (1986) The cholesterol storage disorder of the mutant BALB/c mouse. A primary genetic lesion closely linked to defective esterification of exogenously derived cholesterol and its relationship to human type C Niemann-Pick disease. J Biol Chem 261: 2772-2777.
14. 14. Jelinek D, Heidenreich RA, Erickson RP, Garver WS (2010) Decreased Npc1 gene dosage in mice is associated with weight gain. Obesity (Silver Spring) 18: 1457-1459.
15. 15. Jelinek D, Millward V, Birdi A, Trouard TP, Heidenreich RA, et al. (2011) Npc1 haploinsufficiency promotes weight gain and metabolic features associated with insulin resistance. Hum Mol Genet 20: 312-321.
16. 16. Jelinek D, Castillo JJ, Heidenreich RA, Garver WS (2015) The C57BL/6J Niemann-Pick C1 mouse model with decreased gene dosage is susceptible to increased weight gain when fed a high-fat diet: Confirmation of a gene-diet interaction. Gene 568: 112-113.
17. 17. Liu R, Zou Y, Hong J, Cao M, Cui B, et al. (2017) Rare Loss-of-Function Variants in NPC1 Predispose to Human Obesity. Diabetes 66: 935-947.
18. 18. Xiao J, Wang F, Liu Z, Yang C (2013) Telocytes in liver: electron microscopic and immunofluorescent evidence. J Cell Mol Med 17: 1537-1542.
19. 19. Brunham LR, Kruit JK, Verchere CB, Hayden MR (2008) Cholesterol in islet dysfunction and type 2 diabetes. J Clin Invest 118: 403-408.
20. 20. Heydemann A (2016) An Overview of Murine High Fat Diet as a Model for Type 2 Diabetes Mellitus. J Diabetes Res 2016: 2902351.
21. 21. Bril F, Cusi K (2016) Nonalcoholic Fatty Liver Disease: The New Complication of Type 2 Diabetes Mellitus. Endocrinol Metab Clin North Am 45: 765-781.
22. 22. Michael MD, Kulkarni RN, Postic C, Previs SF, Shulman GI, et al. (2000) Loss of insulin signaling in hepatocytes leads to severe insulin resistance and progressive hepatic dysfunction. Mol Cell 6: 87-97.
23. 23. Garver WS, Jelinek D, Oyarzo JN, Flynn J, Zuckerman M, et al. (2007) Characterization of liver disease and lipid metabolism in the Niemann-Pick C1 mouse. J Cell Biochem 101: 498-516.
24. 24. Ottinger EA, Kao ML, Carrillo-Carrasco N, Yanjanin N, Shankar RK, et al. (2014) Collaborative development of 2-hydroxypropyl-β-cyclodextrin for the treatment of Niemann-Pick type C1 disease. Curr Top Med Chem 14: 330-339.
25. 25. Xu J, Dang Y, Ren YR, Liu JO (2010) Cholesterol trafficking is required for mTOR activation in endothelial cells. Proc Natl Acad Sci U S A 107: 4764-4769.
26. 26. Raleigh D, Zhang X, Hastoy B, Clark A (2017) The β-cell assassin: IAPP cytotoxicity. J Mol Endocrinol 59: R121-r140.
27. 27. Westermark P, Andersson A, Westermark GT (2011) Islet amyloid polypeptide, islet amyloid, and diabetes mellitus. Physiol Rev 91: 795-826.
28. 28. Lyu J, Yang EJ, Head SA, Ai N, Zhang B, et al. (2018) Astemizole Inhibits mTOR Signaling and Angiogenesis by Blocking Cholesterol Trafficking. Int J Biol Sci 14: 1175-1185.
29. 29. Head SA, Shi WQ, Yang EJ, Nacev BA, Hong SY, et al. (2017) Simultaneous Targeting of NPC1 and VDAC1 by Itraconazole Leads to Synergistic Inhibition of mTOR Signaling and Angiogenesis. ACS Chem Biol 12: 174-182.
30. 30. Christensen AA, Gannon M (2019) The Beta Cell in Type 2 Diabetes. Curr Diab Rep 19: 81.
31. 31. Bensellam M, Jonas JC, Laybutt DR (2018) Mechanisms of β-cell dedifferentiation in diabetes: recent findings and future research directions. J Endocrinol 236: R109-r143.
32. 32. Zhu Y, Liu Q, Zhou Z, Ikeda Y (2017) PDX1, Neurogenin-3, and MAFA: critical transcription regulators for beta cell development and regeneration. Stem Cell Res Ther 8: 240.
33. 33. Babu DA, Deering TG, Mirmira RG (2007) A feat of metabolic proportions: Pdx1 orchestrates islet development and function in the maintenance of glucose homeostasis. Mol Genet Metab 92: 43-55.